We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+44.51%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$350M
AUM Growth
+$53.9M
Cap. Flow
+$19M
Cap. Flow %
5.43%
Top 10 Hldgs %
33.5%
Holding
108
New
29
Increased
39
Reduced
21
Closed
18

Top Buys

Rank Stock Value
1
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$9.42M
2
NUVL
Nuvalent
NUVL
+$7.29M
3
BIIB icon
Biogen
BIIB
+$6.21M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$4.88M
5
TERN
Terns Pharmaceuticals
TERN
+$4.56M

Top Sells

Rank Stock Value
1
VCYT icon
Veracyte
VCYT
+$10.8M
2
APEN
Apollo Endosurgery, Inc.
APEN
+$6.26M
3
AKRO
Akero Therapeutics
AKRO
+$5.48M
4
COGT icon
Cogent Biosciences
COGT
+$5.3M
5
NKTX icon
Nkarta
NKTX
+$4.77M

Sector Composition

Rank Sector Weight
1 Healthcare 83.01%
2 Miscellaneous 16.91%
3 Technology 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXDX
1
PUT
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$19M 5.43%
172,400
-32,300
-16% -$2.09M
MDGL icon
2
Madrigal Pharmaceuticals
MDGL
$12.3B
$14.5M 4.14%
+49,898
New +$4.88M
BLU
3
DELISTED
BELLUS Health Inc.
BLU
$14M 4.02%
1,707,370
+51,595
+3% +$481K
PSTX
4
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$11.8M 3.38%
2,230,000
-324,277
-13% -$1.48M
VRAY
5
DELISTED
ViewRay, Inc.
VRAY
$10.8M 3.08%
2,405,360
+81,294
+3% +$354K
XENE icon
6
Xenon Pharmaceuticals
XENE
$5.81B
$10M 2.86%
253,655
+7,663
+3% +$279K
AKRO
7
DELISTED
Akero Therapeutics
AKRO
$9.43M 2.7%
172,100
-127,900
-43% -$5.48M
AVXL icon
8
PUT
Anavex Life Sciences
AVXL
$277M
$9.33M 2.67%
1,007,700
+65,200
+7% +$697K
IMVT icon
9
Immunovant
IMVT
$8.51B
$9.22M 2.64%
519,614
+219,614
+73% +$2.77M
NUVL
10
DELISTED
Nuvalent
NUVL
$9.02M 2.58%
302,963
+261,524
+631% +$7.29M
MORF
11
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$8.95M 2.56%
334,535
+10,114
+3% +$276K
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$31.7B
$8.95M 2.56%
37,652
+5,107
+16% +$1.09M
MDGL icon
13
PUT
Madrigal Pharmaceuticals
MDGL
$12.3B
$8.71M 2.49%
+30,000
New +$2.93M
AKRO
14
CALL
DELISTED
Akero Therapeutics
AKRO
$8.22M 2.35%
+150,000
New +$6.43M
AKRO
15
PUT
DELISTED
Akero Therapeutics
AKRO
$8.22M 2.35%
+150,000
New +$6.43M
ITCI
16
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$7.43M 2.13%
140,366
+4,240
+3% +$212K
ORIC icon
17
Oric Pharmaceuticals
ORIC
$1.37B
$7.28M 2.08%
1,236,296
+27,304
+2% +$92.2K
TERN
18
DELISTED
Terns Pharmaceuticals
TERN
$7.13M 2.04%
700,000
+685,527
+4,737% +$4.56M
MRSN
19
DELISTED
Mersana Therapeutics
MRSN
$6.68M 1.91%
45,607
+5,844
+15% +$988K
BIIB icon
20
Biogen
BIIB
$32.3B
$6.09M 1.74%
+21,975
New +$6.21M
CERS icon
21
Cerus
CERS
$534M
$5.96M 1.71%
1,634,014
+17,555
+1% +$66.2K
CVRX icon
22
CVRx
CVRX
$78.6M
$5.77M 1.65%
314,584
+6,664
+2% +$82.2K
ACRS icon
23
Aclaris Therapeutics
ACRS
$885M
$5.55M 1.59%
352,193
-191,583
-35% -$3.08M
RXDX
24
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$5.5M 1.57%
+50,000
New +$3.24M
CINC
25
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$4.86M 1.39%
+395,382
New +$9.42M
1
2 3 4 5

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Silverarc Capital Management held 108 positions worth $350M, up 18% from $296M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Silverarc Capital Management deployed $19M of net new capital in Q4 2022, opening 29 new positions and adding to 39 existing holdings. Its largest new stake was CinCor Pharma, Inc. Common Stock: 395,382 shares worth $4.86M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 80% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the largest reduction was Veracyte, an estimated $10.8M trimmed.

  • Silverarc Capital Management's largest Q4 2022 buy was CinCor Pharma, Inc. Common Stock: 395,382 shares worth $4.86M.
  • Silverarc Capital Management added most to Nuvalent in Q4 2022, an estimated $7.29M increase.
  • Silverarc Capital Management's biggest Q4 2022 reduction was Veracyte, cutting an estimated $10.8M.
  • Silverarc Capital Management fully exited Apollo Endosurgery, Inc. in Q4 2022, selling an estimated $6.26M.
  • Silverarc Capital Management's ten largest holdings make up 33% of its $350M portfolio in Q4 2022.
  • Silverarc Capital Management opened 29 new positions and closed 18 in Q4 2022.
  • Silverarc Capital Management's portfolio value rose 18% quarter-over-quarter to $350M.

Based on Silverarc Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.